# Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene Amplification

> **NCT03888092** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sunshine Lake Pharma Co., Ltd.** · enrollment: 81 (actual)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Z650

## Key facts

- **NCT ID:** NCT03888092
- **Lead sponsor:** Sunshine Lake Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-18
- **Primary completion:** 2022-12-13
- **Final completion:** 2022-12-13
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2023-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03888092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03888092, "Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene Amplification". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03888092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*